1 Kohansal R, "The natural history of chronic airflow obstruction revisited: an analysis of the Framing-ham offspring cohort" 180 : 3-10, 2009
2 Calverley PM, "Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease" 356 : 775-789, 2007
3 Burge PS, "Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDEtrial" 320 : 1297-1303, 2000
4 Mathers CD, "Projections of global mortality and burden of disease from 2002 to 2030" 3 : e442-, 2006
5 Yoo KH, "Prevalence of chronic obstructive pulmonary disease in Korea: the fourth Korean National Health and Nutrition Examination Survey, 2008" 16 : 659-665, 2011
6 Donohue JF, "Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium" 182 : 155-162, 2010
7 Pauwels RA, "Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease" 340 : 1948-1953, 1999
8 Vestbo J, "Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial" 353 : 1819-1823, 1999
9 Vestbo J, "Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial" 353 : 1819-1823, 1999
10 Vogelmeier C, "Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium" 11 : 135-, 2010
1 Kohansal R, "The natural history of chronic airflow obstruction revisited: an analysis of the Framing-ham offspring cohort" 180 : 3-10, 2009
2 Calverley PM, "Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease" 356 : 775-789, 2007
3 Burge PS, "Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDEtrial" 320 : 1297-1303, 2000
4 Mathers CD, "Projections of global mortality and burden of disease from 2002 to 2030" 3 : e442-, 2006
5 Yoo KH, "Prevalence of chronic obstructive pulmonary disease in Korea: the fourth Korean National Health and Nutrition Examination Survey, 2008" 16 : 659-665, 2011
6 Donohue JF, "Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium" 182 : 155-162, 2010
7 Pauwels RA, "Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease" 340 : 1948-1953, 1999
8 Vestbo J, "Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial" 353 : 1819-1823, 1999
9 Vestbo J, "Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial" 353 : 1819-1823, 1999
10 Vogelmeier C, "Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium" 11 : 135-, 2010
11 Global Initiative for Chronic Obstructive Lung Disease I. Global initiative for chronic Obstructive Lung Disease (GOLD), "Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease"
12 Halbert RJ, "Global burden of COPD: systematic review and meta-analysis" 28 : 523-532, 2006
13 Anthonisen NR, "Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study" 272 : 1497-1505, 1994
14 Caverley PMA, "Chronic obstructive pulmonary disease" Chapman and Hall 419-424, 1995
15 Godtfren NS, "COPD-related morbidity and mortality after smoking cessation: status of the evidence" 32 : 844-853, 2008
16 Buhl R, "Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD" 38 : 797-803, 2011
17 대한결핵및호흡기학회, "2014개정 COPD 진료지침" 2014